FLT3 and lymphoma: Here we clearly demonstrated that the VRP-FLT3 vaccination overcame the intrinsic self-tolerance mechanisms to induce a strong antibody response to FLT3 in the tumor-bearing mice in both of our leukemia and lymphoma models.